Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
Search
Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
More
Search
Home
Tags
EMA
EMA
Press Releases
Entrada Therapeutics Receives EU Authorization to Start Exon 45 Skipping Clinical Trial in Duchenne Muscular Dystrophy
Approved Treatments
EMA Recommends EU Approval for Duvyzat (givinostat) to Treat Duchenne Muscular Dystrophy
Press Releases
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
Editorials
Givinostat EMA Approval: Is Givinostat (Duvyzat) Approved by EMA?
Press Releases
Three Ongoing Clinical Trials of Elevidys Gene Therapy Temporarily Halted in Europe
Press Releases
Translarna (Ataluren) Rejected by EMA: Marketing Authorization Not Renewed
DMD
Explore Of 5 Phases In Drug Development
Press Releases
European Clinical Trial Map Launched
Editorials
Call from Families to European Medicines Agency (EMA): Re-examine Ataluren (Translarna)
1
2
Page 1 of 2
Popular
Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy
DMD Warrior
-
December 26, 2024
Must Read
Press Releases
Translarna (Ataluren) Rejected by EMA: Marketing Authorization Not Renewed
Editorials
DMD WarrioR’s Turkish Representative Shares His Views on Elevidys Gene Therapy: Is It Effective and Why Is It Expensive?
Research
Fn14 Protein May Protect Muscle Stem Cells, Offering Promise for Development of Duchenne Treatments